Group items tagged

HayMax, maker of the famous organic drug-free allergen barrier balm has been awarded the 'British Made Award' for Best British Allergy Product 2022. The award celebrates businesses that work tirelessly to make their region one of the most diverse and dynamic the UK has to offer. HayMax MD and creator Max Wiseberg comments: "This award means a great deal to us. We've always been proud that our products have been manufactured in the UK. We are passionate about reducing the cost to the environment so being British-made means we keep the miles down and reduce our carbon footprint." HayMax balms are manufactured in the UK. It buys local to reduce the cost to the environment, even if it means it costs a bit more. HayMax's current pots are now made in the UK, which has been great for reducing their carbon footprint. Its tins come from London. The new pots can be recycled and re-used. The brand has now switched to using sugar cane to make its pots and has also reduced the amount of material used in the pots by just over 54%. And they have switched from the plastic labels to paper labels.

The minimum Covid-19 self-isolation period in England will be cut to five days from seven if someone tests negative twice, health secretary Sajid Javid said on Thursday (January 13) - a move that could reduce staffing disruption in businesses and infrastructure. The rapid spread of the Omicron variant has fuelled a spike in Covid-19 cases to record highs in Britain, and the surge has cause major disruption to the staffing of hospitals, schools and transport as staff have to self-isolate. "We've made the decision to reduce the minimum self-isolation period to five full days in England," Javid told parliament. "From Monday, people can test twice before they go, leaving isolation at the start of day six." The government had previously reduced isolation period to seven days from 10 days to people in England who get a negative result on a rapid lateral flow test two days in a row.

In partnership with the pharmaceutical company Boehringer Ingelheim, Leeds Teaching Hospitals Trust (LTHT) has recently established an innovative cardiometabolic clinic. The clinic focuses on reducing cardiovascular risk in people with diabetes who have recently been discharged from LTHT following a heart attack. It is delivered jointly by the cardiology department at Leeds General Infirmary and the diabetes services at the Trust. This is a patient-centred approach to reducing that risk, with pharmacist-delivered clinics scheduled for six to eight weeks after the heart attack. Stephen Wheatcroft, Professor of Cardiometabolic Medicine and Consultant Cardiologist at LTHT, said: "This is an exciting and innovative development, one of the first in the country. Previously, Type 2 diabetic patients presenting with heart issues would have been treated by two separate specialty teams. This is the first time there has been a specific clinic combining the cardiac and diabetes team working together. "We aim to reduce the risk for patients, with earlier multidisciplinary hospital care, to help discharged patients achieve better diabetes control, through improved medication support and optimisation, reducing the need for further treatment and future hospital stays. Overall, it will mean a better patient experience, with improved monitoring and information about treatment options, along with a reduction in waiting times for review in a specialist clinic."

Esperion Therapeutics' non-statin therapy "bempedoic acid" has shown modest results in reducing the risk of major cardiovascular events in statin-intolerant patients in the cholesterol lowering via bempedoic acid, an ACL-inhibiting regimen (CLEAR Outcomes) trial, revealed GlobalData, a leading data and analytics company. As a result, there is substantial room for improvement in this space as a potential approval is expected in Australia in near-term based on these results, said GlobalData. According to GlobalData's Pharmaceutical Intelligence Center, the total number of diagnosed prevalent cases of dyslipidemia in Australia is expected to increase at a compound annual growth rate of approximately 1.2% from 5.2 million in 2022 to 5.4 million in 2025. Neha Myneni, Pharma Analyst at GlobalData, comments: "Bempedoic acid joins several statin alternatives that have shown the potential to reduce cardiac illnesses. However, with not much significant improvement in the outcomes, there exists a clear room for improvement for non-statin therapies in this space." Bempedoic acid is the sixth class of cholesterol-lowering drugs (other than cholesteryl-ester transfer protein isoform (CETPi) inhibitors), that has demonstrated the potential to reduce heart attacks and strokes. Other class of therapies with similar potential currently marketed in Australia include statins, bile acid resins, niacin, ezetimibe, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors (alirocumab, evolocumab, and inclisiran).

Ketamine therapy has a swift short-term effect on reducing symptoms of depression and suicidal thoughts, a recent study has revealed. The research has been published in the 'British Journal of Psychiatry Open'. A systematic review led by the University of Exeter and funded by the Medical Research Council analysed evidence from 83 published research papers. The strongest evidence emerged around the use of ketamine to treat both major depression and bipolar depression. Symptoms were reduced as swiftly as one to four hours after a single treatment and lasted up to two weeks. Some evidence suggested that repeated treatment may prolong the effects, however more high-quality research is needed to determine by how long. Similarly, single or multiple doses of ketamine resulted in moderate to large reductions in suicidal thoughts. This improvement was seen as early as four hours following ketamine treatment and lasted on average three days, and up to a week.

The Royal Pharmaceutical Society (RPS) has backed a new framework from NHS England to reduce inappropriate prescribing of addiction-causing medicines. It believes that the new framework is a positive step towards improving patient care by supporting medicine reviews and shared decision making to help people reduce their use of medicines that are no longer providing much clinical benefit. The society has also welcomed investment in innovative approaches to supporting patients and urged all pharmacists to refer people to such schemes. Director for England at RPS, James Davies said: "Pharmacists are well-placed to help reduce inappropriate prescribing of high strength painkillers such as opioids and other addictive medicines. "Pharmacy teams can also often spot repeat purchases of over the counter medicines by patients so are well placed to intervene and give advice on the management of chronic pain. Whilst opioids can play an important part in helping people with chronic pain there has long been a need for alternative approaches that are safer and more effective for patients.

A new Information Standard has been published to support improved medication and sharing of allergy information across healthcare services in England. The move will standardise medication message content and help reduce medicines related errors and improve patient safety. It will also allow efficient sharing of medicine information between NHS and social care organisations, including hospitals, GP practices, residential care homes, mental health trusts, and community pharmacies. The Standard that came into effect in October "will save healthcare professionals valuable time accessing key medicines information, provide clinicians with access to a richer source of information, consistent across all care settings", said Shahzad Ali, NHS Digital clinical lead for the Interoperable Medicines Programme.

The regulators have reduced the notice periods for change to supplementary opening hours for community pharmacy contractors from 1 October 2022. Following the Pharmaceutical Services Negotiating Committee (PSNC)'s discussions with the Department of Health and Social Care (DHSC) and NHS England as part of Year 4 negotiations, it has been agreed that the required notice periods for changes to supplementary opening hours will reduce to five weeks. Community pharmacy contractors who want to change their supplementary opening hours are required by their terms of service to notify NHS England. "If a contractor wants to increase supplementary opening hours at the pharmacy, this can be done with no notice - but notification of the change must still be given to NHS England," said PSNC. "To decrease supplementary opening hours at the pharmacy, at least five weeks' notice must be given to NHS England prior to implementing the change."

NHS England has commissioned the Royal Pharmaceutical Society (RPS) to develop guidance that helps community and hospital pharmacy teams across Britain to reduce the impact of pharmacy services, pharmaceutical care and medicines on the environment. The RPS said the Greener Pharmacy Guidance will enable pharmacies to self-assess their impact against the standards, benchmark and improve through evidence-based activities and actions. "I'm delighted our strong commitment to helping pharmacy reduce its environmental impact can now be taken to the next level through developing guidance and accreditation for pharmacy teams," RPS president Professor Claire Anderson said. "Medicines account for 25 per cent of carbon emissions within the NHS and this initiative underscores our commitment to promoting sustainable healthcare and supporting the NHS's goal of achieving 'net zero' emissions by 2040." Peter Morgan, medicines assistant director at NHS England, commented: "Pharmacy staff are involved in the purchasing and dispensing of almost every medicine used in the NHS and the new Greener Pharmacy Guidance and Self-accreditation scheme will provide support for pharmacy professionals by outlining clear actions to deliver more environmentally sustainable pharmacy practices." The RPS said the guidance and digital self-assessment toolkit will integrate with carbon calculator tools to help pharmacy teams to measure their carbon footprint, action plan to reduce use of carbon and improve sustainability.

Scottish community pharmacies will now hold two Naloxone kits, available in either nasal spray or injectable form, essential for reversing opioid overdoses. The Emergency Access Naloxone Scheme, which is backed by £300,000 of Scottish Government funding, began on Monday (30 October). Drugs and Alcohol Policy Minister Elena Whitham said, "Through our National Mission to reduce drug deaths and harms, we have invested more than £3 million in widening access to Naloxone, including through our emergency services." Witham said this new nationwide service is a welcome addition to existing services. "Police Scotland recently completed a force-wide rollout to 12,500 officers who have used the kits more than 300 times. According to the most recent statistics, 70 per cent of those who are at risk of opioid overdose are being provided with a lifesaving kit," she added. "It provides a substantial increase in life-saving emergency access and I'm grateful to all those in community pharmacies who are supporting our £250 million National Mission to reduce drug deaths," Whitham said.

The Department of Health and Social Care (DHSC) has suggested Estradiol patch as an alternative for patients who use 1 pump of Oestrogel daily. DHSC has updated Annex A of SSP022 and SSP023 for Oestrogel Pump-Pack 0.06 per cent gel to include a dose conversion to a specific alternative Estradiol patch. Previously, only dose conversions for patients using 2 to 4 pumps daily were included in Annex A of SSP022 and SSP023. Separately, the supporting guidance for three SSPs which allow quantity restriction have been updated to reflect the requirement to endorse the reduced quantity supplied in accordance with these SSPs. SSP019 - Oestrogel pump-pack 0.06% gel SSP020 - Ovestin 1mg cream SSP021 - Premique low dose 0.3mg/1.5mg modified release tablets "When endorsing an SSP for a reduced quantity, contractors must ensure that the correct SSP number is endorsed along with the product name and the reduced quantity supplied in accordance with the SSP," said PSNC.

The National Institute for Health and Care Excellence (NICE) has recommended icosapent ethyl also called Vazkepa manufactured by Amarin for adults who have cardiovascular disease with controlled LDL-C levels taking a statin. It's final draft guidance is expected to be available on the July 20. Nearly half a million people are expected to benefit from the first licensed treatment shown to reduce the risk of heart attacks and strokes in people with controlled low-density lipoprotein cholesterol (LDL-C - sometimes called "bad" cholesterol) who are taking a statin and who have raised levels of triglycerides. NICE said: "Clinical trial evidence suggests that for people with raised triglycerides who have LDL-C levels controlled by statins, and who have cardiovascular disease, icosapent ethyl reduces their risk of cardiovascular events by over a quarter compared with placebo. Helen Knight, interim director of medicines evaluation at NICE, said: "Icosapent ethyl is the first licensed treatment of its kind for people who are at risk of heart attacks and strokes despite well controlled LDL cholesterol because they have raised blood fats. And although lifestyle changes, including diet and exercise, can help to reduce their risk, these may not work for everyone.

British pharmacies and slimming clinics are reducing prices for weight-loss drugs Wegovy and Mounjaro in a competitive bid to win patients. Both Novo Nordisk's Wegovy (semaglutide) and Eli Lilly's Mounjaro (Tirzepatide) injection drugs are cleared for weight loss in combination with a reduced-calorie diet and increased physical activity. Wegovy was launched in the UK market in September, with Mounjaro following in February. Initially designed for treating type 2 diabetes, the drugs have been found to also induce weight loss by suppressing appetite and decelerating digestion. As reported by Reuters, Simple Online Pharmacy has further reduced the price of starter doses of Mounjaro to £149 for a one-month supply. In February, the price was cut to £159 ($198) from £179. Additionally, the pharmacy on Monday discounted the higher Mounjaro strengths that patients take later.

The government has launched a new 'Better Health' campaign to help people working towards healthier weight and reduce the risk of being hospitalised with Covid-19. The campaign launched in partnership with 15 weight management and physical activity partners will provide both free and discounted offers for weight management. Public health minister Maggie Throup said the campaign will focus on improving adults' health and help them to achieve a healthier weight. It will also include focus on the risk of serious diseases such as type 2 diabetes, heart disease and up to 12 types of cancer, to reducing the probability of hospitalisation with Covid-19. Besides highlighting these health conditions, the campaign will emphasise how these could be prevented by losing excess weight.

Members of the Royal Pharmaceutical Society (RPS) highlighted the work of pharmacists in making medicines use and the whole NHS more environmentally sustainable at the Welsh Senedd this week. Politicians present were informed that around 25 per cent of the NHS' carbon emissions result from medicines use, and therefore pharmacists' expert skills are crucial for reducing these emissions. RPS Wales Director, Elen Jones, was among the RPS staff who attended the event, which was co-hosted with the Association of the British Pharmaceutical Industry. Commenting on the event, Elen said: "It was great to get so many productive conversations with the politicians to highlight the great work pharmacists are already doing in the sustainability field and to explain what further steps are required to reduce the negative environmental and ecological impact of medicines."

Members of the Pharmacists' Defence Association (PDA) who have benefits in the Boots Pension Scheme have sought support from their union following the recent communications from the trustees about the removal of the option to retire at 60 without a reduced pension. The company claimed that retirement between 60-65 years old without a reduced pension was a discretionary benefit, and it has ended with the buy-in deal with Legal and General. However, PDA members believe there is insufficient evidence to fully support this claim, and therefore they are questioning whether this option should have been secured as part of the buy in and not ended with immediate effect. PDA Union national officer, Paul Moloney said: "Instead, we believe benefit statements issued to members, at the very least are contradictory, and clearly state that a full pension will be payable from a member's 60th birthday, with no reference to this benefit being discretionary and therefore subject to a regular review by the trustees. Instead, the benefit statements give the impression that an unreduced pension from 60 is a right with no indication that retirement plans should not be based on the benefit statements."

In a strategic move to enhance healthcare delivery, the NHS has announced plans to intensify the utilisation of virtual wards under the the Urgent and Emergency Care Recovery Plan. The NHS virtual wards are aimed to reduce avoidable hospital admissions across England. This follows a comprehensive analysis revealing significant benefits from virtual wards over the past year. "Virtual wards offer a transformative approach to healthcare delivery, allowing patients to receive medical care from the comfort of their own homes," remarked NHS national director for urgent and emergency care, Sarah-Jane Marsh. "This initiative not only reduces the burden on hospital resources but also ensures that patients receive timely and personalised care."

The NHS Confederation has urged the government to reconsider its 'living with Covid' plan and introduce mitigating actions that will help avoid further critical incidents being declared at the NHS front-line. The organisation said the high rates of Covid is having a major impact on the delivery of health services and slowing down efforts to reduce large waiting lists, noting that the country has been in the grip of another spike in Covid cases resulting from the Omicron BA.2 variant. With more than 20,000 patients now in hospital with Covid (or who have Covid but are in hospital for other reasons) and high staff absences, NHS is facing huge operational challenges, harming efforts to reduce waiting times in other areas, it said.

In its first, the National Institute for Health and Care Excellence (NICE) has recommended the use of Pre Exposure Prophylaxis (PrEP) to treat people at the highest risk of catching HIV. The announcement comes along with a consultation on draft guideline by NICE on reducing sexually transmitted infections. NICE's recommendation is backed up by the government's HIV Action Plan to hit zero new transmissions of HIV by 2030. The pill prevents HIV by stopping the virus from crossing into the healthy cells and replicating. According to the UK PROUD study, PrEP reduced the risk of HIV infection by 86 per cent for men who have sex with men. However, people taking the pill must also get regular HIV testing and STI screening done every three months.

The Pharmacists' Defence Association (PDA) has expressed concerns over Boots UK's decision to reduce supplemental opening hours at some pharmacies. The association stated: "Some pharmacists and other staff at Boots are being notified this week of changes to opening hours at their place of work, with local briefings taking place. The PDA are supporting their members to deal with any potential impact on their employment." It said that reducing pharmacy opening hours would affect patients' access to a trusted healthcare professional, especially if it is being done by the largest community pharmacy multiple. It even called upon the NHS to adequately fund community pharmacies to ensure they remain open when patients and local communities need their services. Meanwhile, Boots management has informed PDA that most of its employees are not pharmacists, and "less pharmacists are expected to be directly impacted by these changes than other colleagues," PDA said.